Reumuth Mary

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
9
Insider Sells Sum
$112,585.60

Insider Activity of Reumuth Mary

According to the SEC Form 4 filings, Reumuth Mary, being in a position of

  1. CHIEF FINANCIAL OFFICER at Kala Pharmaceuticals, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 7176 shares for $38,921,
    over all time since 2021-06-28, has bought 0 shares, and sold 39545 shares for $112,586.

The largest sale of all time was on 2021-10-26 and amounted to 18898 shares of Kala Pharmaceuticals, Inc. for $34,016.

Biography of Reumuth Mary

No biography is available at this moment.

2024-06-26SaleKala Pharmaceuticals, Inc.
KALA
CHIEF FINANCIAL OFFICER
4,163
0.1526%
$4.75$19,774+28.91%
2024-05-31SaleKala Pharmaceuticals, Inc.
KALA
CHIEF FINANCIAL OFFICER
1,786
0.0575%
$6.09$10,877-11.46%
2024-01-04SaleKala Pharmaceuticals, Inc.
KALA
CHIEF FINANCIAL OFFICER
1,227
0.0438%
$6.74$8,270-2.14%
2023-01-04SaleKala Pharmaceuticals, Inc.
KALA
CHIEF FINANCIAL OFFICER
60
0.002%
$28.54$1,712-66.29%
2022-10-26SaleKala Pharmaceuticals, Inc.
KALA
CHIEF FINANCIAL OFFICER
194
0.0125%
$6.51$1,263+128.67%
2022-06-27SaleKala Pharmaceuticals, Inc.
KALA
CHIEF FINANCIAL OFFICER
2,613
0.0036%
$0.37$967-16.76%
2022-01-04SaleKala Pharmaceuticals, Inc.
KALA
CHIEF FINANCIAL OFFICER
5,700
0.0079%
$1.30$7,410-72.68%
2021-10-26SaleKala Pharmaceuticals, Inc.
KALA
CHIEF FINANCIAL OFFICER
18,898
0.0291%
$1.80$34,016-61.94%
2021-06-28SaleKala Pharmaceuticals, Inc.
KALA
CHIEF FINANCIAL OFFICER
4,904
0.0079%
$5.77$28,296-72.03%
Company
About Prismo.proPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.